Company Overview

AbCellera Biologics Inc. is a Canadian biotechnology company focused on the discovery and development of antibody-based medicines. The company operates at the intersection of biotechnology, artificial intelligence, data science, microfluidics, and high-throughput screening to identify therapeutic antibodies for pharmaceutical and biotechnology partners. AbCellera’s business model is centered on providing antibody discovery capabilities through research collaborations, licensing arrangements, and downstream economic participation in partnered drug programs, including milestone payments and royalties.

The company’s primary revenue drivers include research fees from collaboration agreements, milestone payments tied to clinical and regulatory progress, and royalty interests in commercialized therapeutics. AbCellera serves large pharmaceutical companies, emerging biotechnology firms, and government-related research initiatives. The company gained broad industry recognition through its collaboration with Eli Lilly during the COVID-19 pandemic, which led to the rapid discovery of bamlanivimab. Founded in 2012 by Carl Hansen and colleagues as a spinout from the University of British Columbia, AbCellera evolved from an academic antibody discovery platform into a publicly traded biotechnology company listed on Nasdaq under the ticker ABCL.

Business Operations

AbCellera organizes its operations around integrated antibody discovery and drug development technologies rather than traditional commercial therapeutic divisions. Its core platform combines single-cell screening, microfluidics, genomics, machine learning, and data analytics to identify antibodies from natural immune responses. The company operates advanced laboratory infrastructure and proprietary software systems designed to accelerate therapeutic antibody discovery for infectious diseases, oncology, metabolic disorders, and immunology applications.

The company conducts operations primarily through its Canadian facilities while supporting global partnerships across North America, Europe, and Asia. Key assets include its proprietary antibody discovery engine and internal manufacturing capabilities being expanded through the development of the AbCellera Headquarters Campus in Vancouver. AbCellera has established partnerships with organizations including Eli Lilly, Regeneron, Moderna, and several biotechnology firms. The company also maintains internal therapeutic programs intended to generate wholly owned or co-developed antibody assets alongside partnered programs.

Strategic Position & Investments

AbCellera’s strategic direction emphasizes expanding from a discovery-platform company into a more vertically integrated biotechnology organization with internal drug development capabilities. Growth initiatives include increasing the number of partnered antibody discovery programs, advancing proprietary therapeutic candidates, and investing in manufacturing and translational infrastructure. The company has continued investing in artificial intelligence-enabled antibody design, computational biology, and rapid response capabilities for emerging infectious diseases.

Major investments include the construction and expansion of research and manufacturing facilities in Vancouver, supported in part by Canadian federal and provincial funding initiatives. AbCellera has also invested in technology platforms intended to improve antibody optimization, developability, and clinical translation. The company’s strategy includes selective ownership stakes in internally developed drug candidates and broader participation across the biologics value chain. Public filings and investor materials indicate continued focus on oncology, inflammation, metabolic disease, and pandemic preparedness technologies.

Geographic Footprint

AbCellera is headquartered in Vancouver, British Columbia, Canada, and maintains operations primarily in North America, while supporting a global collaboration network with pharmaceutical and biotechnology companies. Its research, laboratory, and technology infrastructure are concentrated in Canada, though the company’s commercial relationships extend internationally through licensing and discovery agreements.

The company’s market presence reaches multiple regions including North America, Europe, and parts of Asia-Pacific through strategic partnerships and therapeutic development programs. AbCellera’s collaborations with multinational pharmaceutical companies provide international operational exposure and access to global drug development and commercialization channels. The company’s antibody discovery technologies are used in programs targeting diseases with worldwide commercial markets and regulatory pathways.

Leadership & Governance

AbCellera was co-founded by Dr. Carl Hansen, who has played a central role in shaping the company’s scientific and strategic direction. Leadership has emphasized combining advanced computation, engineering, and biology to modernize antibody drug discovery and improve the speed and precision of therapeutic development. Public company disclosures and executive commentary consistently describe a long-term strategy focused on platform scalability, scientific innovation, and internal pipeline expansion.

Key executives include:

• Dr. Carl Hansen – Chief Executive Officer
• Andrew Booth – Chief Financial Officer
• Dr. Jane Pritchard – Chief Strategy Officer
• Marnie Gray – Chief Legal Officer and Corporate Secretary
• Dr. Andrew MacKinnon – Chief Scientific Officer

The company operates under a board and governance structure consistent with Nasdaq-listed biotechnology companies and provides oversight through executive leadership, independent directors, and committee governance disclosed in annual filings including SEC Form 10-K and proxy materials.